2,4-thiazolidinedione has been researched along with Diabetic Retinopathy in 4 studies
thiazolidine-2,4-dione: structure in first source
1,3-thiazolidine-2,4-dione : A thiazolidenedione carrying oxo substituents at positions 2 and 4.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Over a 20-year period, patients on dapagliflozin were projected to experience relative reductions in the incidence of myocardial infarction (MI), stroke, CV death, and all-cause death of 13." | 3.80 | Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. ( Alperin, P; Cohen, M; Dziuba, J; Goswami, D; Grossman, HL; Hardy, E; Iloeje, U; Perlstein, I; Racketa, J, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dziuba, J | 1 |
| Alperin, P | 1 |
| Racketa, J | 1 |
| Iloeje, U | 1 |
| Goswami, D | 1 |
| Hardy, E | 1 |
| Perlstein, I | 1 |
| Grossman, HL | 1 |
| Cohen, M | 1 |
| Ambrosius, WT | 1 |
| Danis, RP | 1 |
| Goff, DC | 1 |
| Greven, CM | 1 |
| Gerstein, HC | 1 |
| Cohen, RM | 1 |
| Riddle, MC | 1 |
| Miller, ME | 1 |
| Buse, JB | 1 |
| Bonds, DE | 1 |
| Peterson, KA | 1 |
| Rosenberg, YD | 1 |
| Perdue, LH | 1 |
| Esser, BA | 1 |
| Seaquist, LA | 1 |
| Felicetta, JV | 1 |
| Chew, EY | 1 |
| Colucciello, M | 1 |
| Ryan, E | 1 |
| Sjølie, AK | 1 |
| Møller, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
1 review available for 2,4-thiazolidinedione and Diabetic Retinopathy
| Article | Year |
|---|---|
Medical management of diabetic retinopathy.
Topics: Diabetic Retinopathy; Enzyme Inhibitors; Humans; Hypolipidemic Agents; Protein Kinase C; Protein Kin | 2004 |
1 trial available for 2,4-thiazolidinedione and Diabetic Retinopathy
| Article | Year |
|---|---|
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
Topics: Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Double-Blind Method; Femal | 2010 |
2 other studies available for 2,4-thiazolidinedione and Diabetic Retinopathy
| Article | Year |
|---|---|
Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Topics: Amputation, Surgical; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Cardiovascul | 2014 |
Macular edema and thiazolidinediones.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypoglycemic Agents; Incidence; Ligands; Ma | 2010 |